Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problematic Internet Use and Family Rules Among Children and Adolescents.

Neuropsychopharmacology reports·2026
Same author

Follicular Lymphoma Developing During IL-17A Inhibitor Therapy in a Patient With Psoriasis: Retreatment Without Lymphoma Progression.

International journal of dermatology·2026
Same author

Family-Based Preventive Interventions for Problematic Internet Use Among Children and Adolescents: Protocol for a Systematic Review and Meta-Analysis.

International journal of environmental research and public health·2026
Same author

Allergy-Aware Protocol for Blenderized Tube Feeding Initiation in Children With Severe Motor and Intellectual Disability.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

Low-Cost Community-Based Personal Alarm Intervention for Preventing Sexual Victimization in Indian Urban Slums: A Cluster Randomized Controlled Trial.

Journal of interpersonal violence·2026
Same author

The DOCK3-HAUS7 axis: A new paradigm in optic nerve regeneration.

Neural regeneration research·2026

Related Experiment Video

Updated: Mar 15, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.8K

Dock3-NMDA receptor interaction as a target for glaucoma therapy.

Atsuko Kimura1, Kazuhiko Namekata2, Xiaoli Guo1

  • 1Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Histology and Histopathology
|September 13, 2016
PubMed
Summary

Dedicator of cytokinesis 3 (Dock3) protein protects retinal ganglion cells in glaucoma by reducing NMDA receptor expression, offering a novel neuroprotective strategy beyond intraocular pressure reduction.

More Related Videos

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K
Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity
07:11

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity

Published on: September 19, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 15, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.8K
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K
Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity
07:11

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity

Published on: September 19, 2025

1.2K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Cell Biology

Background:

  • Glaucoma is a leading cause of blindness characterized by retinal ganglion cell (RGC) death and optic nerve damage.
  • Current glaucoma therapy primarily targets reducing intraocular pressure (IOP), but neuroprotection offers a complementary approach.
  • Dedicator of cytokinesis 3 (Dock3) exhibits neuroprotective properties in the retina and optic nerve.

Purpose of the Study:

  • To review the therapeutic potential of neuroprotection for glaucoma.
  • To explore the role of Dock3 in regulating N-methyl-D-aspartate (NMDA) receptors in the context of glaucoma.
  • To discuss apoptosis signal-regulating kinase 1 (ASK1) as a potential therapeutic target.

Main Methods:

  • Review of existing literature on glaucoma, neuroprotection, Dock3, NMDA receptors, and ASK1.
  • Discussion of in vivo studies demonstrating Dock3's effect on NMDA receptor internalization and degradation.
  • Analysis of the proposed mechanism involving Fyn kinase inhibition.

Main Results:

  • Dock3 directly binds to the GluN2B subunit of NMDA receptors.
  • Overexpression of Dock3 promotes NMDA receptor internalization and degradation, mediated by Fyn inhibition.
  • Reduced NMDA receptor expression leads to decreased excitotoxicity and oxidative stress, promoting RGC survival.

Conclusions:

  • Dock3-mediated NMDA receptor regulation presents a promising neuroprotective strategy for glaucoma.
  • Targeting Dock3 or downstream pathways could mitigate RGC damage in glaucoma.
  • ASK1 represents an innovative therapeutic target for managing oxidative stress in glaucoma.